The profound effects of solid tumour-induced B cell dysregulation

Solid tumours evade immunosurveillance through a plethora of mechanisms. It remains elusive how the development and functions of B cells vary in different tumour contexts. Here, we observed distinct patterns of B cell abnormality in triple-negative breast cancer and termed these patterns “tumour-induced B cell abnormality” type (TiBA). TiBA results from disrupted early B cell development in the bone marrow, which is associated with abnormal myelopoiesis. This study highlights the heterogeneity of tumour-induced systemic changes on B cells and lays foundation for the precision treatment of patients with different B cell abnormalities. Overall design: To study the B cells changes in response to tumour burden at single-cell level, we collected the peripheral blood (PB) or bone marrow (BM) cells from sham (naive) mice or mice-bearing orthotopic triple-negative breast cancer tumours including, PyMT-N, T11, T12, 2208L) and performed scRNA-seq.